ABSTRACT
INTRODUCCIÓN: La azitromicina constituye una alternativa antibiótica en la diarrea bacteriana. Existen pocos datos en España de sensibilidad a azitromicina de enteropatógenos. Métodos Se determinaron las CMI de azitromicina por E-test en aislados de Salmonella no typhi (SNT), Shigella y Yersinia de los últimos 3 años (2010-2012). También se estudió la sensibilidad a los antibióticos habitualmente utilizados en la clínica diarreica mediante un método de microdilución. Resultados De las 139 cepas de SNT, Shigella y Yersinia, 138 tuvieron una CMI ≤ 16 mg/l de azitromicina. En adultos, el 14,7 y el 40,6% de las cepas de SNT y Shigella, respectivamente, mostraron resistencia al menos a 2 de los siguientes antibióticos: amoxicilina, cotrimoxazol y ciprofloxacino. En población pediátrica, el 10% de los aislados de SNT y el 28,6% (2/7) de Shigella presentaron resistencia combinada a amoxicilina y cotrimoxazol. Conclusiones La azitromicina sería una elección antibiótica útil en el tratamiento de diarrea bacteriana en nuestro medio
INTRODUCTION: Azithromycin represents an alternative option to treat bacterial diarrhea when the antibiotic therapy is indicated. Little is known regarding the susceptibility to azithromycin in enteropathogensin Spain. METHODS: TheMICs of azithromycin were determined by E-test against Salmonella non-typhi(SNT), Shigella and Yersinia isolates collected over the last three years (2010-2012). In addition, the susceptibility to other antibiotics usually used to treat gastrointestinal diseases was determined in these isolates by using a microdilution method. RESULTS: A total of 139 strains of SNT, Shigella and Yersinia were studied. All of them, except one strain, had a MIC ≤ 16 mg/L of azithromycin. In the adult population, 14.7% and 40.6% of SNT and Shigella isolates, respectively, were resistant to at least 2 of following antibiotics: amoxicillin, trimethoprim-sulfamethoxazole and ciprofloxacin. In the pediatric population, 10% of SNT clinical isolates and 28.6% (2/7) of Shigella isolates were resistant to amoxicillin and trimethoprim-sulfamethoxazole. CONCLUSIONS: In our experience, azithromycin would be a useful antibiotic alternative to treat bacterial diarrea
Subject(s)
Humans , Microbial Sensitivity Tests/methods , Yersinia/pathogenicity , Shigella/pathogenicity , Salmonella/pathogenicity , Azithromycin/pharmacokinetics , Yersinia Infections/microbiology , Dysentery, Bacillary/microbiology , Salmonella Infections/microbiology , Diarrhea/microbiologyABSTRACT
INTRODUCTION: Azithromycin represents an alternative option to treat bacterial diarrhea when the antibiotic therapy is indicated. Little is known regarding the susceptibility to azithromycin in enteropathogens in Spain. METHODS: The MICs of azithromycin were determined by E-test against Salmonella non-typhi (SNT), Shigella and Yersinia isolates collected over the last three years (2010-2012). In addition, the susceptibility to other antibiotics usually used to treat gastrointestinal diseases was determined in these isolates by using a microdilution method. RESULTS: A total of 139 strains of SNT, Shigella and Yersinia were studied. All of them, except one strain, had a MIC≤16mg/L of azithromycin. In the adult population, 14.7% and 40.6% of SNT and Shigella isolates, respectively, were resistant to at least 2 of following antibiotics: amoxicillin, trimethoprim-sulfamethoxazole and ciprofloxacin. In the pediatric population, 10% of SNT clinical isolates and 28.6% (2/7) of Shigella isolates were resistant to amoxicillin and trimethoprim-sulfamethoxazole. CONCLUSIONS: In our experience, azithromycin would be a useful antibiotic alternative to treat bacterial diarrhea.
